Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HLB Pharmaceutical Co., Ltd (047920.KQ)
Namyangju-Si, KR
HLB Pharmaceutical Co., Ltd is a South Korean pharmaceutical firm dedicated to the research and development of peptide-based drugs. Its product line encompasses a wide array of pharmaceutical preparations. These include medications for skeletal muscle relaxation, tranquilizing effects, antihistamine action, hypertension management, pain alleviation, anti-itching, astringent properties, anti-inflammatory relief, alimentary system support, metabolic regulation, ophthalmic conditions, local anesthesia, anti-arteriosclerosis, expectoration, fever reduction, analgesia, diabetes control, chemotherapy, peptic ulcer treatment, central nervous system issues, bacterial infections (antibiotics), digestive assistance, antacid needs, dental care, multivitamin supplementation, parasitic skin diseases, dermatological concerns, urogenital organ function, amino acid replacement, cough suppression, mucus thinning, parasitic worm elimination, diarrhea relief, circulatory system disorders, vitamin deficiencies, skin softening, hemorrhoid treatment, and liver ailments. Additionally, the company is actively developing CTT-004, an investigational therapy for ataxia associated with spinocerebellar degeneration, and offers Contract Manufacturing Organization (CMO) services. The enterprise, established in 1998, was formerly recognized as Mediforum Pharmaceutical Incorporation before adopting the name HLB Pharmaceutical Co., Ltd in October 2020. Its headquarters are located in Namyangju-Si, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.15% | -12.41% | -31.85% | -23.98% | -23.39% | -29.86% | -39.38% | -24.71% | -23.69% | +45.20% | +47.38% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+50.0% ★ Q1'26: +89.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+118.8% ★ Q1'26: -55.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-2.5% Q1'26: -3.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+0.5% Q1'26: +1.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+0.8% Q1'26: +2.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+3.5% Q1'26: +3.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.00× ★ Q1'26: 2.29× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex Healthcare 266420.KS | 0.32% | 145.5K | 0.09% |
| 2 | Samsung Kodex Fn Growth ETF 325010.KS | 0.04% | 38.4K | 0.30% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 123.1K | 0.29% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 10.6K | 0.46% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 28.5K | 0.28% |
| 6 | Invesco Dow Jones Islamic Global Developed Markets UCITS ETF IGDA.L | 0.00% | 2.2K | 0.40% |
| 7 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 11.6K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jae-Hyung Park | Chief Executive Officer & Executive Director | — | male |
| Kyung-Won Park | Director of Sales | — | male |
| Man-Gyu Kim | Vice President of Strategic Planning & Executive Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 047920.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
